ORLANDO, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO Gareth ...

In addition, AVERSA Buprenorphine, our next candidate ... Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain ...

In addition, AVERSA Buprenorphine, our next candidate ... Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain ...

Following this, Nutriband plans to launch AVERSA Buprenorphine ... is working on developing AVERSA™ Fentanyl, a fentanyl transdermal system aimed at deterring abuse, which could potentially ...

Following this, Nutriband plans to launch AVERSA Buprenorphine, with estimated peak sales of ... Nutriband is working on developing AVERSA™ Fentanyl, a fentanyl transdermal system aimed at deterring ...

In addition, AVERSA Buprenorphine, our next candidate for AVERSA is projected ... including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system ...